Abstract
Prostate cancer is (PCa) the second leading cause of cancer death in males in the United State, with 174,650 new cases and 31,620 deaths estimated in 2019. It has been documented that epigenetic deregulation such as histone modification and DNA methylation contributes to PCa initiation and progression. EZH2 (enhancer of zeste homolog 2), the catalytic subunit of the Polycomb Repressive Complex (PRC2) responsible for H3K27me3 and gene repression, has been identified as a promising target in PCa. In addition, overexpression of other epigenetic regulators such as DNA methyltransferases (DNMT) is also observed in PCa. These epigenetic regulators undergo extensive post-translational modifications, in particular, phosphorylation. AKT, CDKs, PLK1, PKA, ATR and DNA-PK are the established kinases responsible for phosphorylation of various epigenetic regulators.
Document Type
Review
Publication Date
12-2020
Digital Object Identifier (DOI)
https://doi.org/10.1016/j.gendis.2019.10.018
Funding Information
NIH R01 CA157429 (X. Liu), R01 CA192894 (X. Liu), R01 CA196835 (X. Liu), R01 CA196634 (X. Liu). The work was also partially supported by University of Kentucky Cancer Center (P30 CA177558).
Repository Citation
Wang, Ruixin and Liu, Xiaoqi, "Epigenetic Regulation of Prostate Cancer" (2020). Toxicology and Cancer Biology Faculty Publications. 97.
https://uknowledge.uky.edu/toxicology_facpub/97
Notes/Citation Information
Published in Genes & Diseases, v. 7, issue 4.
© 2019 Chongqing Medical University
This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).